Navigation Links
CoLucid (CLCD) Alert: Johnson & Weaver, LLP Launches an Investigation into the Fairness of Price and Process in Proposed Sale of CoLucid Pharmaceuticals, Inc.; Is $46.50 a Fair Price?
Date:1/18/2017

SAN DIEGO, Jan. 18, 2017 /PRNewswire/ -- Shareholder rights law firm Johnson & Weaver, LLP has launched an investigation into whether the board members of CoLucid Pharmaceuticals, Inc. (NASDAQ: CLCD) breached their fiduciary duties in connection with the proposed sale of the Company to Eli Lilly and Company. CoLucid is a biopharmaceutical company that develops small molecules for the acute treatment of migraines.

On January 18, 2017, CoLucid announced it had signed a definitive merger agreement with Eli Lilly. Under the terms of the agreement, Eli Lilly will acquire all shares of CoLucid Pharmaceuticals for a purchase price of $46.50 per share.

The investigation concerns whether the CoLucid board failed to satisfy their duties to the Company shareholders, including whether the board adequately pursued alternatives to the acquisition and whether the board obtained the best price possible for CoLucid shares of common stock. Nationally recognized Johnson & Weaver is investigating whether the proposed deal price represents adequate consideration, especially given one Wall Street analyst has a $58 price target on the stock. 

If you are a shareholder of CoLucid and believe the proposed buyout price is too low and you're interested in learning more about the investigation or your legal rights and remedies, please contact lead analyst Jim Baker (jimb@johnsonandweaver.com) at 619-814-4471.

About Johnson & Weaver, LLP:
Johnson & Weaver, LLP is a nationally recognized shareholder rights law firm with offices in California, New York and Georgia. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. For more information about the firm and its attorneys, please visit http://www.johnsonandweaver.com. Attorney advertising. Past results do not guarantee future outcomes.

Contact:
Johnson & Weaver, LLP
Jim Baker, 619-814-4471
jimb@johnsonandweaver.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/colucid-clcd-alert-johnson--weaver-llp-launches-an-investigation-into-the-fairness-of-price-and-process-in-proposed-sale-of-colucid-pharmaceuticals-inc-is-4650-a-fair-price-300392666.html


'/>"/>
SOURCE Johnson & Weaver, LLP
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky Notifies Investors with Losses on Their Investment in Incyte Corporation of Class Action Lawsuit and the May 6, 2013 Lead Plaintiff Deadline
2. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces Investigation into Possible Breaches of Fiduciary Duty by the Board of PROLOR Biotech, Inc. in Connection with the Sale of the Company to OPKO Health, Inc.
3. SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Trius Therapeutics, Inc. - TSRX
4. Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Vical Incorporated
5. SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ambit Biosciences Corporation. - AMBI
6. Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness"
7. SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Impax Laboratories, Inc. - IPXL
8. INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Puma Biotechnology, Inc. (PBYI) To Contact The Firm
9. Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Puma Biotechnology, Inc.
10. SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Orexigen Therapeutics, Inc.
11. SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Avalanche Biotechnologies, Inc. - AAVL
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/11/2019)... ... June 11, 2019 , ... Mytonomy, the leader ... leader in opioid treatment, announced today they are partnering to combat the opioid ... deployed its virtual care platform at the Mayo Clinic to drive shared decision ...
(Date:5/31/2019)... ... May 29, 2019 , ... ... the USPTO providing proprietary interest to our methodology, processes, and diagnostic techniques. ... AND TREATMENT… extends Somnology’s IP rights including our proprietary sleep scoring methodology. ...
(Date:5/21/2019)... ... May 21, 2019 , ... DuPont Nutrition ... opened the inaugural Africa Brewing Conference dedicated to sharing brewing knowledge, strengthening relationships ... event, which is supported through a partnership with “Ethiopia Invest”, will run through ...
(Date:5/8/2019)... ... ... Standing at 16.2 hands, Atlas is on the large side for a Quarter Horse. ... among other activities. When loping around a corner in late 2017, Atlas tripped and ... to only being able to walk. Fortunately Atlas’ owner, Kelly, sought the opinion of ...
Breaking Biology Technology:
(Date:7/17/2019)... ... July 18, 2019 , ... Flagship ... James, HT, PMP, to its executive team as Vice President of Operations. Ms. ... development. In her new role, Ms. James is responsible for ensuring on-time delivery ...
(Date:7/17/2019)... , ... July 15, 2019 , ... ... science expertise exclusively for Life Sciences and Healthcare companies, announces the availability of ... advisory services and strategic direction to start-up and emerging bio-pharma companies interested in ...
(Date:7/17/2019)... (PRWEB) , ... July 16, 2019 , ... Imagine using ... or to detect bone loss before it causes osteoporosis. For South Dakota School of ... “This is potentially a game-changer in terms of our ability to monitor and prevent ...
Breaking Biology News(10 mins):